Outlook Therapeutics (OTLK) Return on Invested Capital: 2017-2020
- Outlook Therapeutics' Return on Invested Capital rose 375.00% to 6.93% in Q2 2020 from the same period last year, while for Jun 2020 it was 6.93%, marking a year-over-year increase of 375.00%. This contributed to the annual value of 1.90% for FY2019, which is 100.00% up from last year.
- According to the latest figures from Q2 2020, Outlook Therapeutics' Return on Invested Capital is 6.93%, which was up 8.94% from 6.36% recorded in Q3 2019.
- In the past 5 years, Outlook Therapeutics' Return on Invested Capital ranged from a high of 6.93% in Q2 2020 and a low of 0.82% during Q4 2017.
- Moreover, its 3-year median value for Return on Invested Capital was 4.77% (2019), whereas its average is 4.64%.
- Data for Outlook Therapeutics' Return on Invested Capital shows a peak YoY skyrocketed of 427bps (in 2019) over the last 5 years.
- Quarterly analysis of 4 years shows Outlook Therapeutics' Return on Invested Capital stood at 0.82% in 2017, then reached 2.09% in 2018, then surged by 427bps to 6.36% in 2019, then surged by 375bps to 6.93% in 2020.
- Its last three reported values are 6.93% in Q2 2020, 6.36% for Q3 2019, and 3.18% during Q2 2019.
